BIA Separations offers bioprocessing technology for the development of advanced therapeutics

18 June 2020
Image:ThisIsEngineering

BIA Separations has introduced its novel PrimaS ligand technology. The proprietary multi-use platform faciliates high-resolution and high speed processing and says BIA, addresses many critical separation problems in fast emerging advanced therapy medicinal products (ATMPs).

BIA Separations has introduced its novel PrimaS ligand technology. The proprietary multi-use platform faciliates high-resolution and high speed processing and says BIA, addresses many critical separation problems in fast emerging advanced therapy medicinal products (ATMPs). The first application of PrimaS technology being made available is for mRNA purification addressing a growing interest in mRNA-based therapies.

As part of BIA Separations‘ CIMmultus range, PrimaS is a key addition to the company‘s mRNA purification toolbox, including Oligo dT-18, C4-HLD and SDVB chemistries. The platform harnesses mRNA capturing and polishing strategies, including dsRNA impurity removal and mRNA sizing options. All technologies are easily scalable from lab to manufacturing, and are designed to provide better product quality than traditional purification systems.

mRNA manufacturing involves several complex bioprocessing steps beginning with plasmid DNA production and its linearisation, followed by in vitro transcription (IVT). Both operations include finely balanced enzymatic reactions, utilising a number of key raw materials. For the standards required for clinical applications, ultra-pure mRNA is required, with critical contaminants eliminated, including dsRNA, template DNA and respective enzymes, in addition to potential impurities from raw materials such as chromatin-like structures and endotoxins.

Significant progress has been made by reseachers globally to sharpen concepts that exploit mRNA-based therapeutics, with as examples, many protein replacement, immuno-oncology and vaccine approaches, already progressing to early clinical stages. COVID-19 exemplifies the need for these advancements, acting as a catalyst to now further accelerate such developments.

Suggested Reading

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free